Diabetes mellitus (DM), or impaired glucose tolerance, is concurrently present in 50--80% of patients with pancreatic cancer (PC), one of the most rapidly fatal malignancies. DM is a known risk factor for PC[@b1][@b2][@b3]; furthermore, new-onset DM could be an early sign of PC[@b4], resulting from insulin resistance induced by a paraneoplastic syndrome[@b5] or pancreatic β-cell dysfunction[@b6].

Increasing evidence suggests that patients with colorectal, breast, liver, endometrial, and gastric cancers and leukemia[@b7][@b8] who also have DM are at increased risk of cancer recurrence, cancer-related death, and death from any cause. However, whether and how the concurrent DM may affect clinical outcome in PC has not been determined, and available information on this topic is limited and inconsistent. Some studies found that DM did not have a significant effect on overall survival (OS) duration[@b9][@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23], whereas others found that DM was associated with significantly reduced survival duration[@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34]. These inconsistent findings may be partially explained by small sample sizes and/or by not adjusting for body mass index (BMI), disease stage, and other possible confounders[@b35]. Understanding the prognostic relevance of DM in PC may lead to better clinical management of this devastating disease. We therefore conducted a systematic review and meta-analysis to illustrate the association between preexisting DM and mortality in patients with PC.

Methods
=======

Data sources and searches
-------------------------

We searched PubMed, Embase, and Web of Science (TS) databases from their inception to September 2, 2014, for articles evaluating the association between DM and outcome in PC, including survival, stage at diagnosis, and treatment choice. Our overall search strategy included terms for diabetes (e.g., "diabetes," "glucose intolerance," and "hyperglycemia"), pancreatic cancer (e.g., "cancer," "carcinoma," "adenocarcinoma," "pancreatic," and "pancreas"), and prognosis (e.g., "prognosis," "survival," and "mortality"). We also searched the references of included articles. No language or publication type restrictions were imposed ([Supplementary Table 1](#S1){ref-type="supplementary-material"}).

Study selection
---------------

Our overall search targeted articles describing studies that met the following three criteria: 1) evaluated any prognostic outcome by DM or glycemic status; 2) evaluated a PC patient population; and 3) contained original data analysis. We included studies evaluating type 1 and/or type 2 DM. To avoid overlapping patient populations, we compared data on recruitment years, data source, and geographic location. Publications with duplicate datasets were triaged by keeping the most recent one, the one with the larger study population, or the one with multivariate-adjusted estimates. Articles that met the above three criteria and reported all-cause mortality or OS were included in our systematic review ([Fig. 1](#f1){ref-type="fig"}). To be included in our meta-analysis, articles had to report a risk estimate (e.g., hazard ratio \[HR\]) relating preexisting DM to subsequent death by using survival analysis regression models, with an estimate of precision, such as standard error (SE) or 95% confidence interval (CI). Articles with missing risk estimates were also included in the meta-analysis if the risk estimates were generated by author contact. Of the 14 authors contacted, 7 responded, 6 provided additional information. We also conducted a systematic review or meta-analyses on long-term, cancer-specific mortality, disease-free survival (DFS), progression-free survival (PFS), postoperative death rate, and choice of cancer treatment in studies with the relevant information including studies that were excluded from the general review and meta-analysis because of overlapping study durations[@b36][@b37][@b38].

Data extraction and quality assessment
--------------------------------------

Each article was abstracted by one author and reviewed by the second author for accuracy. Any disagreement was resolved by consensus. If several estimates were reported in the same article, we chose the most fully adjusted estimate (i.e., multivariate regression was selected over univariate regression, which was selected over unadjusted Kaplan-Meier analysis). If an article reported multiple estimates by subgroup only, these estimates were entered separately into our relevant meta-analysis dataset.

We also extracted information on key indicators of study quality with use of Meta-analysis of Observational Studies in Epidemiology (MOOSE) standards[@b39] for reporting of meta-analyses of observational studies. From each study, we chose the risk estimates that represented the greatest degree of control for potential confounders. Quality was assessed by using elements of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement[@b40].

Data analyses
-------------

The results of the systematic review were summarized qualitatively. The null hypothesis of "no additional mortality risk in cancer patients with preexisting DM" was tested with use of a nonparametric sign test.

For the meta-analysis, *P* values quoted at less than the specified threshold were assumed to be at the threshold, resulting in a conservative estimate of the significance level. *I*^2^ and Cochran *Q* estimates were performed in a heterogeneity assessment[@b41]. A *I*^2^ value of \>50% or a *P* value of less than 0.1 represented significant heterogeneity. A DerSimonian-Laird random-effects model (D + L) was used to calculate the pooled HR. Otherwise, an inverse variance fixed-effects model (I-V) was selected. The meta-analysis was performed with use of Stata version 12.0 software (Stata Corp, College Station, TX).

To assess the impact of study quality, we conducted sensitivity analyses. We considered studies to be of higher quality and calculated separate pooled HRs if they were population-based (n = 4) or were adapted from full articles (n = 28), with estimates adjusted for confounders (n = 23) and DM evaluated as the primary exposure variable (n = 10). Publication bias was evaluated by using Begg's funnel plot. We performed the Duval and Tweedie nonparametric trim and fill procedure[@b42] to further assess potential effects of publication bias. This method considers the possibility of hypothetical missing studies, imputes their HRs, and recalculates a pooled estimate. For all tests, a *P* value (two-sided) of less than 0.05 was considered statistically significant.

Results
=======

Of the 4, 463 titles identified, 487 abstracts and 135 resulting full articles were reviewed to determine their eligibility ([Fig. 1](#f1){ref-type="fig"}). Three additional articles were identified by searching references[@b9]. Of these 138 articles, 59 addressed the effect of DM on PC outcome. Eighteen of the 59 articles were excluded from the review for overlapping study duration, lack of definition for DM, or lack of focus on OS. As a result, 41 articles were included in the systematic review of the association of preexisting DM with long-term, all-cause mortality. Twenty-nine of these 41 articles with 33 risk estimates were included in the meta-analysis ([Fig. 1](#f1){ref-type="fig"})[@b9][@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b18][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50]. Descriptive data for studies included are listed in [Table 1](#t1){ref-type="table"} and [Supplementary Table 2](#S1){ref-type="supplementary-material"}.

Description of studies
----------------------

Forty-one studies had been conducted in the United States (n = 17), Europe (n = 13), Asia (n = 10), and Canada (n = 1). Sample sizes ranged from 21 to 22, 439 with a median of 367. Across the 41 studies that reported the number of participants with DM, the overall prevalence of DM was 35.7% (range, 9.7%--54.9%). Across the 34 studies that reported participant sex, 64.8% of the study population was male. Reporting of age and follow-up time varied widely across studies.

Survival analyses reported various outcomes, including cumulative one-year mortality rates, OS, DFS, and PFS. The studies used a variety of analytic techniques including 9 studies using Kaplan-Meier survival analysis only, 32 using Cox proportional hazards regression analysis (only 29 had exact HRs and 95% CIs), which were included in the following meta-analysis ([Supplementary Table 3](#S1){ref-type="supplementary-material"}). The time origin for survival analysis was generally the time of cancer diagnosis, except in the case of treatment or surgical cohorts, for which the time of origin was the beginning of treatment or the date of tumor resection. Most studies were clinic-based design and 4 studies were population-based cohorts ([Supplementary Table 3](#S1){ref-type="supplementary-material"}).

Systematic review of evidence
-----------------------------

The best evidence from each study is summarized here. Of 9 studies using Kaplan-Meier survival curves with the log-rank tests, DM was associated with decreased survival in 3 studies[@b33][@b34][@b51] and 4 studies[@b19][@b52][@b53][@b54] with and without statistical significance, respectively. DM was associated with nonsignificantly increased survival in 2 studies[@b55][@b56].

Seven studies provided 9 crude HRs of death for preexisting DM including 3 nonsignificantly decreased risk[@b9][@b45] and 6 null effect[@b13][@b15][@b18][@b44][@b57]. Of the 25 studies with multivariate HRs of death for DM, 12 reported significantly increased risk[@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b47][@b48][@b49], 2 reported nonsignificantly increased risk[@b11][@b16], 2 had significantly decreased risk[@b46][@b50], and 9 had null effect[@b10][@b12][@b14][@b20][@b21][@b22][@b43][@b54][@b58].

Overall, DM was associated with increased risk of death in 25 estimates, decreased risk of death in 4 studies, and null effect in 16 estimates. The nonparametric sign test rejected the null hypothesis of equal mortality in patients with and without preexisting DM (*P* \< 0.001).

Meta-analysis on DM and all-cause mortality
-------------------------------------------

The 29 studies in the meta-analysis reported both risk (HR) and precision (95% CI). The descriptive data, adjustment or restriction variables, and major findings from each study are described in [Table 1](#t1){ref-type="table"}. The results of the meta-analysis are shown in [Fig. 2](#f2){ref-type="fig"}. Preexisting DM was associated with a 13% increased risk of death from all causes in PC patients (HR, 1.13; 95% CI, 1.04--1.22). The pooled HR (95% CI) was 1.37 (1.15--1.63) from 13 studies conducted in patients with resectable disease, 1.07 (0.89--1.29) from 8 studies in unresectable disease, and 1.01 (0.93--1.10) from 10 studies in those with all-stage diseases. The Begg's test and Duval and Tweedie trim and fill procedure showed no significant risk of publication bias (Begg's test *P* = 0.14; Duvall and Tweedie adjusted HR: 1.10; 95% CI: 1.01--1.20; number of imputed studies = 3) ([Supplementary Fig. 1](#S1){ref-type="supplementary-material"}).

Sensitivity analyses
--------------------

Considering the large variations in the covariates included in each study ([Table 1](#t1){ref-type="table"}), we conducted a sensitivity analysis to confirm robustness ([Table 2](#t2){ref-type="table"}). Risk estimates from higher-quality studies were similar to the overall estimate. The pooled risk estimate (HR \[95% CI\]) was 1.21 (1.06--1.39) for studies that took DM as the primary exposure variable. Studies with any adjustments had a pooled HR (95% CI) of 1.13 (1.03--1.24). More specifically, the above pooled HRs (95% CIs) after adjusting for age, BMI, and disease stage were 1.08 (0.98--1.20), 1.17 (0.98--1.39), and 1.09 (0.95--1.26), respectively. The risk estimates did not vary by publication types. The HR (95% CI) was 1.12 (1.03--1.21) for full articles.

Analysis of influence revealed that the risk of all-cause mortality among patients with PC and DM remained significant with the omission of each study in turn. Omission of the study by Cannon *et al.*[@b28] resulted in the lowest pooled estimate (HR: 1.10; 95% CI: 1.02--1.19); omission of the study by Choi *et al.*[@b46] resulted in the highest pooled estimate (HR: 1.14; 95% CI: 1.05--1.24).

DM and cancer-specific mortality
--------------------------------

One study[@b36] provided adjusted HRs of cancer-specific death in patients who had undergone resection. It showed that patients with DM had a significantly higher risk of cancer-specific mortality compared with their non-DM counterparts (HR: 1.37; 95% CI: 1.00--1.89).

Duration of DM and all-cause mortality
--------------------------------------

Six studies[@b20][@b27][@b30][@b33][@b37][@b52] evaluated the association between duration of DM and OS of PC patients. In most studies, two years of diabetes duration was used as the cutoff for defining new-onset and longstanding DM. One study[@b33] demonstrated that both new-onset and longstanding DM were associated with shorter survival by log-rank test. Three studies[@b20][@b37][@b52] did not find a correlation between new-onset DM and OS in PC patients. Two studies[@b27][@b30] indicated that OS duration in PC patients with new-onset DM, but not that in patients with longstanding DM, was significantly shorter than was OS in patients without DM. A meta-analysis of the two studies[@b27][@b30] with risk estimates revealed new-onset DM as a significant prognostic factor (HR: 1.52; 95% CI: 1.20--1.93). We did not detect any significant heterogeneity (I^2^ = 0%, Q = 0.48; *P* = 0.49). However, the same prognostic value was not found in longstanding DM (HR: 1.22; 95% CI: 0.83--1.80) ([Supplementary Fig. 2](#S1){ref-type="supplementary-material"}).

DM and DFS, PFS
---------------

Two studies[@b28][@b38] showed that having DM before undergoing tumor resection was independently associated with poor DFS (pooled HR: 1.54; 95% CI: 1.28--1.85) as well as poor OS after adjusting confounders. No significant heterogeneity was detected in the meta-analysis (I^2^ = 14.3%, Q = 1.17; *P* = 0.28) ([Supplementary Fig. 3](#S1){ref-type="supplementary-material"}). Moreover, two studies[@b17][@b18] found that in patients with advanced PC who were receiving systemic chemotherapy, PFS did not differ between those with and without DM.

DM and treatment selection, postoperative mortality
---------------------------------------------------

No significant difference was found in the percentage of surgery between patients with and without DM, although DM patients were more likely recommended for resection[@b27][@b34]. Patients with DM had a higher likelihood of developing fistulas and acute kidney injury than did those without DM, but overall complication and severity did not differ between them[@b59]. The relation between DM and a higher postoperative mortality was not conclusive[@b59][@b60][@b61][@b62].

Discussion
==========

Our study demonstrated that preexisting DM in PC patients, compared with their non-DM counterparts, was associated with increased risk of all-cause mortality. The risk of all-cause mortality was higher in patients with resected or resectable tumors than in those with nonresectable tumors and was higher in patients with new-onset DM than in those with longstanding DM. These observations could not be explained by confounding factors, publication bias, or undue influence by a single study.

To our knowledge, our meta-analysis is the first exclusive study of the association between DM and PC outcome, even though this topic has been investigated by many individual studies. Our results are not in accordance with a previous meta-analysis of long-term all-cause mortality in cancer patients with preexisting DM by Barone *et al.*[@b8], who found that DM was associated with increased risk of mortality in all cancers (HR: 1.41; 95% CI: 1.28--1.55) but not specifically in PC (HR: 1.09; 95% CI: 0.70--1.69). The discrepancy between the two studies could be partially explained by low power (7%) of the previous study since only four studies in the PC subgroup with a population of 1,681 patients, including 477 DM patients, were analyzed. In the current review and larger-scale meta-analyses, we conducted post hoc power calculations and found that our study had 85% power in demonstrating the association between DM and cancer mortality. Furthermore, we observed that the negative effect of DM on survival occurred primarily in patients with resected or resectable pancreatic tumors (HR, 1.37; 95% CI, 1.15--1.63) but not in patients with late-stage disease (HR, 1.07; 95% CI, 0.89--1.29). These observations support the hypothesis that the previous inconsistent findings between individual studies might be partially explained by the different patient populations involved.

There were several limitations in the literature and thus in our systematic review and meta-analysis. First, studies varied in their inclusion criteria, study population, and adjustment for confounding variables, which may have led to both overestimations and underestimations of risks. Nevertheless, our sensitivity analyses, excluding studies that did not adjust for potential confounders, did not materially change the results. Residual or unknown confounding is still possible after adjusting for most relevant confounding factors. The association may not necessarily be causal as well, particularly in the observational studies[@b63]. Given that the start time of survival of each study differs by cancer stage (ie. tumor resection), we also performed a subgroup analysis by cancer stage (resected/resectable, unresectable and mixed stages), which confirmed the association of diabetes with poor survival in patients with resected/resectable tumor.

Second, the status of DM ascertainment varied across studies, and the duration of DM was not directly reported in some studies. Moreover, in most studies, diabetic status was based exclusively on past medical history; thus, there was a chance of misclassification, which may have led to underestimation of the number of patients with DM and of the effect of the disease.

Third, overlap in patient enrollment between some studies may have elevated their weight in the quantitative analysis. For example, the patient cohort used by Cannon *et al.*[@b28] to derive and test the survival prognostic scoring model included the 209 patients from Chu *et al.*'s prior study[@b27], and these patients were randomly divided into training and validation sets. In addition, two studies conducted at the same institution, i.e., Li *et al.*'s study of all-stage patients recruited between 1999 and 2008 and Sahin *et al.*'s study of patients who had undergone resection and were recruited between 1996 and 2001, may have some overlapping patients. However, we expect that the effects of this overlap on the final results of our analysis to be minimal.

The fourth limitation was that most of the articles did not report the types of anticancer and antidiabetic therapies used or their effects on outcomes. This is important because studies have shown that some therapies (e.g., surgery, adjuvant chemotherapy, and the antidiabetic drug metformin) have a more positive effect than others on cancer outcome[@b64][@b65].

There are several potential explanations for the observed association between decreased survival time and DM in PC patients. First, DM may enhance tumor progression via the mechanisms of insulin resistance and inflammation, i.e., the same mechanisms that contributed to the higher risk of PC may also be responsible for the poor outcome of the disease. It has been suggested that hormonal or metabolic abnormalities, such as hyperinsulinemia or hyperglycemia, may affect tumor biology at multiple stages, including malignant transformation, growth, and metastasis[@b66].

Second, PC patients with DM may be given less vigorous anticancer regimens because they generally have more contradictions to surgery, chemotherapy, and other treatments, although selection bias associated with types of surgery, chemotherapy, and radiotherapy were not seen in previous studies[@b27]. The metabolic abnormalities associated with DM may have an adverse effect on response to cancer treatment[@b67].

Finally, the high mortality rate observed among patients with DM may partially be due to noncancerous factors, such as complications of long-term DM. However, since most PC patients die of the disease within a short period of time, it is unlikely that the complications of long-term DM would make a significant contribution to PC mortality. Only one study measured PC-specific mortality and observed a significant impact of DM[@b36].

Previous studies[@b2][@b6] have shown that new-onset DM, compared with longstanding DM, was associated with greater risk of PC because new-onset DM was a manifestation of subclinical PC. The main implication of our study is that DM is significantly associated with adverse outcome in PC. Subgroup analyses showed that the effect of diabetes on overall survival was associated with the cancer stages and the duration of diabetes. Our results reveal the need for further prospective studies to confirm DM as a prognostic factor and to assess the possibility of an antidiabetic regimen in the treatment of PC.
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###### Characteristics of 29 studies included in the meta-analysis of the effect of preexisting DM on pancreatic cancer all-cause, long-term mortality.

  Study, year, country                                Date of recruitment (range)                                                  Inclusion criteria                                                                                                          Exclusion criteria                                                                                       Patients with DM No./Total No. (%)                                                               Age at diagnosis (y)                                                Male No. (%)                 Follow-up time (months)                                                                                                                                                 Survival (HR, 95% CI)                                                                                                                                                                                                                     Adjustments
  -------------------------------------------------- ----------------------------- ------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ---------------------------------------- --------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------
  Sperti[@b24], 1996, Italy                                   1970--1992                                                   Pathologically confirmed; resected                                                                                                          NA                                                                                                         62/113 (54.9)                                                                              59.4 (27--81)                                                    66 (58.4)                             NA                                                                                                                                                3.02 (1.38--6.60)[\*](#t1-fn1){ref-type="fn"}                                                                                                                                                                                                      Age, stage, grade
  Neoptolemos[@b9], 2001, UK                                  1994--2000                                                   Pathologically confirmed; resected                                                                                                          NA                                                                                                         85/541 (15.7)                                                                               60 (53--67)                                                     324 (59.9)                        10 (1--25)                                                                                                                             1.93 (0.77--2.17) \[margin positive\] 1.17 (0.85--2.00) \[margin negative\]                                                                                                                                                                                              None
  Sperti[@b10], 2003, Italy                                   1996--2002                                                        Pathologically confirmed                                                                                                               NA                                                                                                          20/60 (33.3)                                                                             66.3 (48 --82)                                                    34 (56.7)                            1--35                                                                                                                                         0.63 (0.32--1.22), *P* = 0.17[†](#t1-fn2){ref-type="fn"}                                                                                                                                                                          Age, sex, SUV, tumor stage, tumor grade, treatment, CA 19--9,
  van de Poll--Franse[@b25], 2007, The Netherlands            1995--2002                                                                   NA                                                                                                                          NA                                                                                                        245/1211 (20.2)                                                                                  NA                                                              NA                                NA                                                                                                                                                        1.16 (1.00--1.34), *P* \< 0.05                                                                                                                                                                                                         Age, sex, stage, treatment
  Li[@b11], 2007, USA                                         1999--2004                                                        Pathologically confirmed                                                                                                               NA                                                                                                         88/378 (23.3)                                                                                   NA                                                          207 (54.8)                        34 (18--90)                                                                                                                                                 1.186 (0.901--1.560), *P* = 0.224                                                                                                                                                                                                          Age, sex, race, stage
  Li[@b26], 2009, USA                                         2004--2008                                                        Pathologically confirmed                                                                                                               NA                                                                                                         221/841 (26.3)                                                                           61.7 (61.0--62.4)                                                  496 (59.0)                     22.1 (20.2--24.0)                                                                                                                                                      1.29 (1.02--1.64)                                                                                                                                                                                                                  Stage, resection, BMI
  Chu[@b27], 2010, USA                                        2000--2007                                                   Pathologically confirmed; resected                                                                                         Other periampullary adenocarcinomas                                                  93/209 (44.5)[‡](#t1-fn3){ref-type="fn"}; new-onset: 55/93 (59.1); longstanding 35/93 (37.6)                                       65 (37--86)                                       103 (49.3)[\*](#t1-fn1){ref-type="fn"}              NA                                                                                1.55 (1.02--2.35), P = 0.04; New--onset DM[§](#t1-fn4){ref-type="fn"} 1.75 (1.10--2.78), *P* = 0.017 Longstanding DM[§](#t1-fn4){ref-type="fn"} 1.30 (0.75--2.25), *P* = 0.36                                                                      Age, sex, ethnicity, BMI, Charlson, comorbidities, smoking, tumor size, node and margin, perineural and lymphovascular invasion, adjuvant therapy
  McWilliams[@b12], 2010, USA                                 2000--2009                                                                   PAC                                                                                                      Missing height, weight, or disease stage                                                                                     472/1529 (30.9)                                                            66.0 (58.0--74.0)[\|\|](#t1-fn5){ref-type="fn"}                                   864 (56.5)                       Median 306 d                                                                                                                                                   1.08 (0.95--1.22), *P* = 0.229                                                                                                                                                                                                    Age (continuous variable), sex, BMI
  Olson[@b13], 2010, USA                                      2004--2008                                                 Over 21 years; pathologically confirmed                                                                                                       NA                                                                                                          47/475 (9.9)                                                                               63.7 ± 10.8                                                     247 (52.0)                            NA                                                                                                                           0.97 (0.42--2.26), *P* = 0.95 \[resected\]; 0.78 (0.47--1.30), *P* = 0.34 \[unresected\]                                                                                                                                                                                       None
  Dandona[@b14], 2011, USA                                    1995--2009                                                                Resected                                                                                                     Undocumented BMI, BMI \< 18.5 kg/m^2^                                                                                        116/355 (32.7)                                                                              65.5 ± 10.2                                                     192 (54.1)                 32.3 (range, 0.56--51.77)                                                                                                                                                 0.855 (0.650--1.124)                                                                                                                                                                                                               Age, sex, N--stage, BMI
  Cannon[@b28], 2011, USA                                     2000--2009                                                                Resected                                                                                                   Margin positive, neoadjuvant chemotherapy                                                                         78/245 (31.8)[¶](#t1-fn6){ref-type="fn"}                                                              67.0 (58.0--74.0)                                                  115 (46.9)                        Median 4.5                                                                                                                                                   1.99 (1.40--2.82), *P* \< 0.001                                                                                                                                                                                                        Tumor size, node and margin
  Morizane[@b15], 2011, Japan                                 2001--2007                              Pathologically confirmed; metastatic PC with gemcitabine first--line therapy                                                                                     NA                                                                                                         171/409 (41.8)                                                                              64 (21--81)                                                     241 (58.9)                         0.4--41.3                                                                                                                                                         0.997 (0.818--1.217)                                                                                                                                                                                                                         None
  Hartwig[@b29], 2011, Germany                                2001--2009                                                                Resected                                                                                           Ampullary carcinomas or carcinomas of the distal bile duct                                                                            151/1071 (14.6)                                                                           65.4 (57.9--71.1)                                                  599 (55.9)                        17 (10--31)                                                                                                                                                  1.53 (1.20--1.94), *P* = 0.0005                                                                                                                                                                                              Age, CA 19-9, TNM staging, grade, margin status
  Vickers[@b16], 2012, Canada                                 2001--2003                                                 Pathologically confirmed; unresectable                                                                                   Prior chemotherapy except for chemoradiation                                                                                    175/569 (30.8)                                                                           63.9 (36.1--92.4)                                                  298 (52.4)                        Median 13.9                                                                                                                                                   1.21 (0.99--1.47), *P* = 0.058                                                                                                                                                                                           Sex, race, performance status, baseline pain intensity
  Ben[@b30], 2012, China                                      2005--2010                                                   Histologically confirmed; resected                                                                                           History of cancers, no FBG test                                                                             107/396 (27.0)[\#](#t1-fn7){ref-type="fn"}                                                                63.1 ± 9.1                                                        (63.5)                          20 (4--62)                                                                                                                                                  1.385 (1.068--1.796), *P* = 0.014                                                                                                                                                                                         Age, sex, CA19-9, node invasion, stage, neural invasion
  Inal[@b18], 2012, Turkey                                    2005--2011                                   ≥18 years; pathologically confirmed; locally advanced or metastatic                                                                                         NA                                                                                                         127/406 (31.3)                                                         63 \[Gemcitabine\], 57 \[Gemcitabine plus Cisplatin\]                                273 (67.2)                            NA                                                                                                                                                              0.93 (0.53--1.62)                                                                                                                                                                                                                           None
  Sahin[@b31], 2012, USA                                      1996--2011                                                   Pathologically confirmed; resected                                                                                                          NA                                                                                                         144/544 (26.5)                                                                                  NA                                                          314 (57.7)                            NA                                                                                                                                                        1.29 (1.02--1.64), *P* = 0.036                                                                                                                                                                                           Perineural invasion, margin status, node status, grade
  Gong[@b43], 2012, USA                                       1995--1999                                                                   PAC                                                                                                                         NA                                                                                                         72/510 (14.1)                                           66.1 \[BMI \< 25 kg/m^2^\],63.2 \[BMI = 25--30 kg/m^2^\], 62.0 \[BMI ≥ 30 kg/m^2^\]                 278 (54.5)                          10.1 y                                                                                                                                                            0.85 (0.64--1.13)                                                                                                                                                                            Age, sex, race, education, BMI, smoking status, stage, tumor grade, tumor site, primary treatment
  Barbas[@b21], 2012, USA                                     1996--2008                                     Pathologically confirmed PAC; underwent pancreaticoduodenectomy                                                                      Significant missing clinicopathological data                                                                                    51/203 (25.1)                                                                \<65 (47.8%); 65--74(36.4%); ≥ 75 (15.8%)                                      106 (52.2)                            NA                                                                                                                                                         1.2 (0.76--1.90), *P* = 0.42                                                                                                                                             Age, adjuvant therapy, coronary artery disease, histology, neoadjuvant therapy, resection margin, perineural Invasion, lymph node, vascular invasion
  Hwang[@b20], 2013, USA                                      2003--2010                                               \>40 years; with a diagnostic code for PAC                                                                                Had PAC before the start of follow-up in THIN                                                                    745/3147 (23.7)[\*\*](#t1-fn8){ref-type="fn"}                                              72.3 ± 10 \[T2DM\], 71.2 ± 11.6 \[non-T2DM\]                                    1524 (48.4)                            NA                                                                                                                                                        1.02 (0.93--1.12), *P* = 0.620                                                                                                                                                                                        Age, sex, resection, history of pancreatitis, Charlson index
  Zhou[@b44], 2013, China                                     2002--2007                                      Pathologically confirmed; resected; underwent pancreatectomy                                                                                             NA                                                                                                         54/114 (47.4)                                                                               64 (31--79)                                                     79 (69.3)                       15.0 (0.2--60)                                                                                                                                                1.218 (0.765--1.941), *P* = 0.406                                                                                                                                                                                                                   None
  Zeiss[@b45], 2013, Germany                                  2009--2010            \>18 years; pathologically confirmed; stage III-IV; received palliative first-line gemcitabine-based chemotherapy                                                        Adjuvant chemotherapy                                                                                                 16/30 (53.3)                                                                               69 (41--82)                                                     17 (56.7)                       5.8 (0.9--23.5)                                                                                                                                                 1.49 (0.69--3.23), *P* = 0.31                                                                                                                                                                                                                     None
  Mizuno[@b22], 2013, Japan                                   1993--2011                                                                   PAC                                                                                                                         NA                                                                                                         256/540 (47.4)                                                                                67 ± 11                                                       322 (59.6)                            NA                                                                                                                                                        0.91 (0.74--1.12), *P* = 0.39                                                                                                                                                                                             Symptoms at diagnosis, PS, CA19-9, stage, treatment
  Lee[@b23], 2013, Korea                                      2007--2010                           Pathologically confirmed; received an operation, chemotherapy, or chemoradiotherapy                  Received only supportive care, palliative surgery; Referred from other hospitals after receiving treatment or refusing treatment                                          57/187 (30.5)                                                                               65 (31--86)                                                     104 (55.6)                      11.7 (2--59.5)                                                                                                                                                  0.81 (0.54--1.21), *P* = 0.312                                                                                                                                                                                             Age, sex, PS, stage, tumor site, size, CA19-9, CEA
  Choi[@b46], 2014, Korea                                     2003--2010                                 Pathologically confirmed PAC; gemcitabine-based palliative chemotherapy                                                                      Double primary advanced malignancies                                                                                        182/345(52.8)                                                                            60.1 (20.0--84.7)                                                  270 (63.5)                     10.3 (9.5--11.1)                                                                                                                                               0.774 (0.605--0.991), *P* = 0.042                                                                                                                                                             PS, disease extent, weight loss at diagnosis (BMI change ≥ 1), weight loss during chemotherapy (BMI change ≥ 1).
  Toriola[@b47], 2014, USA                                    1993--2001                                                               Exocrine PC                                                                                               Missing information on tumor stage or diabetes                                                                                   62/504 (12.3)                                                                                   64                                                          273 (54.2)                            NA               1.52 (1.14--2.04), *P* \< 0.01 (All exocrine pancreas cancer); 1.45 (1.06--2.00), *P* = 0.02 (Excluding pancreatic cancer cases diagnosed within 3 years of enrolment); 2.31 (1.16--4.58), *P* = 0.02 (Localized); 1.17 (0.62--2.20), *P* = 0.65 (Locally advanced); 1.52 (1.04--2.24), *P* = 0.03 (Metastatic).                                                           Age, sex, BMI, race, smoking, stage
  Dong[@b48], 2014, China                                     2009--2012                       Pathologically confirmed potentially resectable PAC; consecutive patients underwent surgery                                    Double cancer with life-threatening phenotype; died in within 30 days after surgery                                                                 34/114 (29.8)                                                                               60 (54--67)                                                     64 (56.1)                             NA                                                                                                                                                      1.820 (1.115--2.972), *P* = 0.017                                                                                                                                                                      Serum calcium level, histologically poorly-differentiated tumor, existence of vessel invasion
  Salem[@b49], 2014, USA                                      2010--2013                             Albumin-bound paclitaxel plus gemcitabine (Gem/nab) after first-line FOLFIRINOX                                                                                   NA                                                                                                             NA/44                                                                                       55                                                          26 (59.1)                             NA                                                                                                                                                         3.8 (1.0--14.3), *P* ≤ 0.05                                                                                                                                                                                                                       NA
  Beg,2014, USA                                               1995--2008                                                               Code for PC                                                                                               Missing information on DM status or follow up                                                                                   1326/4728 (28.0)                                                                                67.2                                                        4617 (97.7)                      3.6 (1.3--7.4)                                                                                                                                                0.91 (0.849--0.974), *P* = 0.0065                                                                                                                                                                                       Age, tobacco use, disease site, stage, chemotherapy, surgery

Abbreviations: CI, confidence interval; BMI, body mass index; DM, diabetes mellitus; FBG, fasting blood glucose; GFR, glomerular filtration rate; ICD-9, International Classification of Diseases, 9th revision; NA, not available; PAC, pancreatic adenocarcinoma; PC, pancreatic cancer; SUV, standardized uptake value; THIN, The Health Improvement Network.

^\*^Data from [Table 1](#t1){ref-type="table"} of Sperti *et al.* study.

^†^Data from Barone *et al.* study.

^‡^DM definition: For patients without documented history of DM, FBG was tested for classification.

^§^New-onset DM: disease duration preceding PDAC diagnosis date of \< 24 mo; longstanding DM: disease duration preceding PDAC diagnosis date of ≥24 mo.

^\|\|^For all patients including those missing DM status and other data.

^¶^DM definition: A past medical history of, a preoperative fasting glucose greater than 125 mg/dL, two or more outpatient random glucose levels above 199 mg/dL.

^\#^DM definition: A self-reported history of DM or a fasting blood glucose level ≥125 mg/dL (6.9 mmol/L) or postprandial blood glucose level ≥11.1 mmol/L.

^\*\*^DM definition: With a diagnostic code for T2DM.

###### Pooled hazard ratios of all-cause mortality in pancreatic cancer patients with and without DM.

  Type of estimate             Studies (estimates), No.    Total patients, No.   Patients with DM, No.  Pooled HR (95% CI)[\*](#t2-fn1){ref-type="fn"}   I^2^, %   *P*
  ---------------------------- -------------------------- --------------------- ----------------------- ------------------------------------------------ --------- ---------
  Total                        29 (33)                            19818                  5257           1.13 (1.04--1.22)                                66.7      \<0.001
  Studies of full articles     28 (32)                            19774                  5257           1.12 (1.03--1.21)                                66.4      \<0.001
  Adjusted for confounders                                                                                                                                         
   Any confounders             23 (25)                            17843                  4757           1.13 (1.03--1.24)                                72.5      \<0.001
   Age                         15 (17)                            14601                  3667           1.08 (0.98--1.20)                                66.8      \<0.001
   BMI                         6 (8)                              3948                   1036           1.17 (0.98--1.39)                                61.2      0.012
   Stage                       12 (14)                            6156                   1523           1.09 (0.95--1.26)                                66.7      \<0.001
  Patient source                                                                                                                                                   
   Population-based            4 (6)                              5372                   1124           1.12 (0.95--1.32)                                59.6      0.030
   Clinic-based studies        25 (27)                            14446                  4133           1.13 (1.02--1.25)                                68.6      \<0.001
  DM exposure type                                                                                                                                                 
   Primary exposure            10 (12)                            11638                  3110           1.21 (1.06--1.39)                                78.6      \<0.001
   One of multiple exposures   19 (21)                            8180                   2147           1.07 (0.96--1.20)                                54.6      0.001
  Cancer Stage                                                                                                                                                     
   Resected or resectable      13 (14)                            4473                   1037           1.37 (1.15--1.63)                                61.2      0.001
   Unresectable                8 (9)                              2214                    718           1.07 (0.89--1.29)                                53.6      0.028
   Mixed stages                10 (10)                            13131                  3502           1.01 (0.93--1.10)                                60.2      0.007

Abbreviations: BMI, body mass index; CI, confidence; interval; DM, diabetes mellitus; HR, hazard ratio.

^\*^Estimates calculated with use of a random-effects model.

[^1]: These authors contributed equally to this work.
